April 19, 2022

Electronic prescriptions: Recent updates

Thanks to Giulia Conforto for collaborating on this article

A note published by the Ministry of Health and the Ministry of Economy and Finance on March 3, 2022 (“Note”), announced that as of January 31, 2022, electronic prescriptions for drugs that are not reimbursed by the National Health System (“NHS”) are operational in parts of the Italian territory. The first regions to implement the system are Piedmont, Valle d’Aosta, Bolzano, Trento, Emilia-Romagna, Sicily, Lombardy, and Veneto. Others are scheduled to follow in the coming months.

Thus, the provisions of the Decree of the Ministry of Economy and Finance of December 30, 2020 (the “Decree”), on the dematerialization of medical prescriptions for drugs not reimbursed by the NHS (known as “white prescriptions”) can finally be applied, one year after the Decree entered into force. This delay was due to technical issues that jeopardized operation of the Decree.

Electronic White Prescriptions (“EWPs”) — as well as electronic “red” prescriptions for drugs that are reimbursed by the NHS — will be available alongside paper prescriptions without replacing them. Indeed, as of yet, there is no obligation for physicians to issue white prescriptions digitally.

The implementation process

As expected, the Decree provided for the dematerialization of white prescriptions as early as January 30 of last year, laying the foundation for a regulatory system and creating an opportunity to establish the flow.

However, for technical and operational reasons the Decree remained unimplemented until January 31, 2022. The technical specifications drawn up by Sogei (the IT company of the Ministry of Economy and Finance) in order to guarantee operability of the Decree were adopted at the end of a complicated process that involved ongoing dialogue between the Ministry of Health, Federfarma, FOFI, and FNOMCeO.

In early 2022, the State General Accounting Office and the regions agreed on a plan for gradual implementation of EWP operating procedures throughout the country.

The regions named above (Piedmont, Valle d’Aosta, Bolzano, Trento, Emilia-Romagna, Sicily, Lombardy, and Veneto) have already started the process of dematerialization of EWPs, and according to the timetable they should be followed by Friuli-Venezia Giulia, Apulia, Basilicata, and Sardinia.

All physicians in the regions that have decided to implement dematerialization of white prescriptions will be able to use this procedure.

As far as pharmacies are concerned, the Note specifies that — regardless of the timetable and given the principle of national circulation as it applies to EWPspharmacies in all regions of Italy must be able to accept EWPs, even pharmacies located in regions that have not yet implemented EWP use.

Modalities for the transmission of electronic prescriptions

Further information on electronic prescriptions concerns the modalities for transmitting them from physicians to patients and from patients to pharmacists. Indeed, a recent decision of the government, published on March 31, 2022, extended the modalities that were introduced in March 2020 during the emergency period (i.e., email, SMS, WhatsApp, or telephone) through the end of the year 2022.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

Close
March 20, 2023
Today, Regulation (EU) 2023/607 extending the transitional provisions for the placing on the market and putting into service of certain medical devices and in vitro diagnostic medical device...
January 31, 2023
Clinical trials: Ministry of Health signed off on decrees that (i) reorganize ethics committees and coordinate their activities, (ii) determine the single tariff for the authorization proced...
December 19, 2022
On 13 December 2022, EMA, European Commission and HMA jointly adopted a recommendation paper on the introduction of decentralised elements in the conduct of Clinical Trials in the EU/EEA
September 21, 2022
Payback for medical devices: Decree quantifying the exceeding of the expenditure ceiling for medical devices at national and regional level for the years 2015, 2016, 2017 and 2018 published ...
September 1, 2022
The 2021 annual law for market and competition addressing, as to the healthcare sector, reimbursement of drugs, intermediate distribution, patent linkage and institutional accreditation of p...
Search by...
Search
Follow us on
Follow us on